Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 7/20 | 0.50 |
| ▸ | MAPT | P10636 | 4/20 | 0.50 |
| ▸ | TP53 | P04637 | 4/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | ABCG2 | Q9UNQ0 | 4/20 | 0.49 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9962031 | 1.00 | KIF11 (0.50) | KIF11MAPTTP53SMN1; SMN2ABCG2 | |
| SCHEMBL8404215 | 1.00 | KIF11 (0.50) | KIF11MAPTTP53SMN1; SMN2ABCG2 | |
| SCHEMBL8403580 | 0.97 | SIRT1 (0.50) | KIF11MAPTTP53SMN1; SMN2ABCG2 | |
| SCHEMBL8403745 | 0.96 | ABCG2 (0.51) | KIF11MAPTTP53SMN1; SMN2ABCG2 | |
| SCHEMBL764575 | 0.95 | TP53 (0.56) | KIF11MAPTTP53SMN1; SMN2ABCG2 | |
| SCHEMBL8404211 | 0.95 | TP53 (0.49) | KIF11MAPTTP53SMN1; SMN2ABCG2 | |
| SCHEMBL8403740 | 0.95 | TP53 (0.57) | KIF11MAPTTP53SMN1; SMN2ABCG2 | |
| SCHEMBL9962097 | 0.94 | KIF11 (0.49) | KIF11MAPTTP53SMN1; SMN2ABCG2 | |
| SCHEMBL9962023 | 0.94 | KIF11 (0.49) | KIF11MAPTTP53SMN1; SMN2ABCG2 | |
| SCHEMBL13050120 | 0.93 | SIRT1 (0.49) | KIF11MAPTTP53SMN1; SMN2ABCG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11613538-B2 | Method of inhibiting or reducing a viral infection | PTC THERAPEUTICS, INC. (US) | 2023-03-28 | — | — | US | disclosed |
| EP-2434891-B9 | METHODS FOR TREATING CANCER AND NON-NEOPLASTIC CONDITIONS | PTC THERAPEUTICS INC (US) | 2021-05-05 | — | — | EP | disclosed |
| US-20200317668-A1 | METHOD OF INHIBITING OR REDUCING A CORONAVIRIDAE VIRUS INFECTION | PTC THERAPEUTICS, INC. | 2020-10-08 | — | — | US | disclosed |
| EP-2434891-B1 | METHODS FOR TREATING CANCER AND NON-NEOPLASTIC CONDITIONS | PTC THERAPEUTICS INC (US) | 2020-07-22 | — | — | EP | disclosed |
| US-20190194188-A1 | METHODS FOR TREATING CANCER AND NON-NEOPLASTIC CONDITIONS | PTC THERAPEUTICS, INC. | 2019-06-27 | — | — | US | disclosed |
| US-20160340354-A1 | METHODS FOR TREATING CANCER AND NON-NEOPLASTIC CONDITIONS | PTC THERAPEUTICS, INC. | 2016-11-24 | — | — | US | disclosed |
| US-20160340354-A1 | METHODS FOR TREATING CANCER AND NON-NEOPLASTIC CONDITIONS | PTC THERAPEUTICS, INC. | 2016-11-24 | — | — | US | disclosed |
| US-9351964-B2 | Methods for treating cancer and non-neoplastic conditions | PTC THERAPEUTICS, INC. (US) | 2016-05-31 | — | — | US | disclosed |
| US-9351964-B2 | Methods for treating cancer and non-neoplastic conditions | PTC THERAPEUTICS, INC. (US) | 2016-05-31 | — | — | US | disclosed |
| US-8703726-B2 | Methods for treating prostate conditions | PTC THERAPEUTICS, INC. (US) | 2014-04-22 | — | — | US | disclosed |
| US-20120157402-A1 | METHODS FOR TREATING BRAIN TUMORS | PTC THERAPEUTICS, INC. | 2012-06-21 | — | — | US | disclosed |
| US-20120157402-A1 | METHODS FOR TREATING BRAIN TUMORS | PTC THERAPEUTICS, INC. | 2012-06-21 | — | — | US | disclosed |
| US-20120157400-A1 | METHODS FOR TREATING KAPOSI SARCOMA | PTC THERAPEUTICS, INC. | 2012-06-21 | — | — | US | disclosed |
| WO-2011150162-A1 | METHODS FOR TREATING VIRAL CONDITIONS | PTC THERAPEUTICS, INC. (US) | 2011-12-01 | — | — | WO | disclosed |
| WO-2010138659-A1 | METHODS FOR TREATING BRAIN TUMORS | PTC THERAPEUTICS, INC. (US) | 2010-12-02 | — | — | WO | disclosed |
| WO-2010138695-A1 | METHODS FOR TREATING NEUROFIBROMATOSIS | PTC THERAPEUTICS, INC. (US) | 2010-12-02 | — | — | WO | disclosed |
| WO-2010138706-A1 | METHODS FOR TREATING BREAST CANCER | PTC THERAPEUTICS, INC. (US) | 2010-12-02 | — | — | WO | disclosed |
| WO-2010138685-A1 | METHODS FOR TREATING PROSTATE CONDITIONS | PTC THERAPEUTICS, INC. (US) | 2010-12-02 | — | — | WO | disclosed |
| WO-2010138758-A1 | METHODS FOR TREATING CANCER AND NON-NEOPLASTIC CONDITIONS | PTC THERAPEUTICS, INC. (US) | 2010-12-02 | — | — | WO | disclosed |
| WO-2010138652-A1 | METHODS FOR TREATING KAPOSI SARCOMA | PTC THERAPEUTICS, INC. (US) | 2010-12-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157402-A1 | METHODS FOR TREATING BRAIN TUMORS | HDGF, VEGFA, FLT4 | KIF11 1658/4885MAPT 1046/4885TP53 61/4885 |
| US-20160340354-A1 | METHODS FOR TREATING CANCER AND NON-NEOPLASTIC CONDITIONS | HDGF, POLRMT, VEGFA | KIF11 2569/4885MAPT 3328/4885TP53 16/4885 |
| US-20190194188-A1 | METHODS FOR TREATING CANCER AND NON-NEOPLASTIC CONDITIONS | HDGF, POLRMT, VEGFA | KIF11 2569/4885MAPT 3328/4885TP53 16/4885 |
| US-20200317668-A1 | METHOD OF INHIBITING OR REDUCING A CORONAVIRIDAE VIRUS INFECTION | SARS1, POLRMT, EIF2AK2 | KIF11 3683/4885MAPT 2964/4885TP53 1818/4885 |
| US-11613538-B2 | Method of inhibiting or reducing a viral infection | SARS1, EIF2AK2, POLRMT | KIF11 3731/4885MAPT 2901/4885TP53 1710/4885 |
| US-20120157400-A1 | METHODS FOR TREATING KAPOSI SARCOMA | HDGF, HIF1AN, VEGFA | KIF11 1065/4885MAPT 3684/4885TP53 17/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.